Drug Trial Radar · NCT03425539
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Jun 21, 2018
Primary completion
Aug 17, 2021
Study completion Sep 2, 2021
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.
Conditions
- Fabry Disease
Interventions
LucerastatDrug
Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
PlaceboDrug
Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Neuropathic Pain Monthly Score: Change From Baseline to Month 6Time frame: From baseline to Month 6 (duration: 6 months)
Locations
49 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Nephrology Research Clinic
Birmingham, Alabama
University of California Irvine
Irvine, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation
Gainesville, Florida
Emory University School of Medicine; Department of Human Genetics
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
University of Iowa Stead Family Children's Hospital - Division of Medical Genetics
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Infusion Associates
Grand Rapids, Michigan
Duke University Medical Center
Durham, North Carolina
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh (UPMC)
Pittsburgh, Pennsylvania
Greenwood Genetic Center
Greenville, South Carolina
Research Baylor Institute of Metabolic Disease
Dallas, Texas
University of Utah - Division of Medical Genetics
Salt Lake City, Utah
Lysosomal and Rare Disorders Research and Treatment Center
Fairfax, Virginia
Royal Melbourne Hospital - Department of Nephrology
Parkville, Australia
Royal Perth Hospital, Department of Nephrology
Perth, Australia
Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse
Vienna, Austria
University Hospital Ghent
Ghent, Belgium
University Hospital Leuven
Leuven, Belgium
M.A.G.I.C Clinic Ltd
Calgary, Canada
Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology
Halifax, Canada
Research Center, Hôpital Du Sacré-Coeur de Montréal
Montreal, Canada
Vancouver Hospital & Health Sciences - Vancouver General Hospital
Vancouver, Canada
Health Sciences Center Winnipeg
Winnipeg, Canada
London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada
Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin
Berlin, Germany
SphinCS GmbH
Höchheim, Germany
Fachinternistische Gemeinschaftspraxis Markgräferland
Mühlheim, Germany
Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie
Würzburg, Germany
Hosp Alma Mater Studiorum
Dublin, Ireland
ASST Monza, Hospital San Gerardo, Nephrology
Monza, Italy
University of Naples Federico II (Nephrology)
Naples, Italy
Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism
Amsterdam, Netherlands
Haukeland University Hospital Helse Bergen HF
Bergen, Norway
University Hospital in Cracow - Dep. of of Allergies and Immunology
Krakow, Poland
Cardinal Wyszynski Institute of Cardiology
Warsaw, Poland
Department of Pediatric Nutrition and Metabolic Diseases; The Children's Memorial Health Institute
Warsaw, Poland
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.